Lancet Respiratory Medicine

Article	Citations
Postoperative CPAP after major abdominal surgery	872
Time to move away from an oxygen-centric model of pulmonary infarction?	571
Concerns regarding a suggested long COVID paradigm – Authors' reply	489
European Respiratory Society International Congress 2022	456
Video laryngoscopy is not the nemesis of direct laryngoscopy	409
Major gaps in childhood pneumonia research priorities remain	325
The course of action for effective anti-cytokine treatment in COVID-19	312
Correction to Lancet Respir Med 2024; 12: 129–40	295
Correction to Lancet Respir Med 2019; 7: 745–56	291
Rituximab for connective tissue disease-associated interstitial lung disease	277
Savolitinib in NSCLC: progress in the MET exon 14 journey	242
Broad protection from SARS-CoV-2 variants without antigen matching	232
Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic?	222
Australia bans engineered stone to prevent silicosis	220
The burden of tuberculosis in Libya	216
Thoracentesis: an old story and some new sources	196
Eat or heat: fuel poverty and childhood respiratory health	185
Interstitial lung disease: a decade of progress and hope	178
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership	178
Predicted bodyweight—a misleading metric for tidal volume titration?	177
Opioids bring peace to patients with IPF cough	173
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress	170
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials	169
Impact of Myanmar's earthquake on respiratory health	165
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis	161

Chronic obstructive pulmonary disease: 10 years of precision-guided success	158
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros	157
US Senate committee investigates asthma inhaler prices	157
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop	155
Predatory publishers appear in PubMed (and your inbox)	154
Advancing precision medicine for acute respiratory distress syndrome	152
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis	152
GOLD report: 2022 update	149
Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement	147
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study	145
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study	145
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial	145
FLiRTing with danger as SARS-CoV-2 variants evolve	145
Long COVID: systemic inflammation and obesity as therapeutic targets	143
Concerns about PRISm	141
Priorities for NICE in health and social care	138
Genetic associations and lung function in IPF: unexpected answers, persistent questions	138
Claudio Castanos—leader in cystic fibrosis care in Argentina	138
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply	138
Solid and semi-solid perspectives in thoracic surgery	131
US EPA signals renewed regulatory scrutiny of toxic air pollution	131
Correction to Lancet Respir Med 2025; 13: 244–55	131
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials	131
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts	131
Association of SARS-CoV-2 infection and persistence with long COVID	130
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study	128
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial	127
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO	125
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial	124
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts	123
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials	122
Correction to Lancet Respir Med 2022; 10: 972–84	121
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis	120
Vaccination in the world's top athletes	119
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta	119
Awake prone positioning in COVID-19: is tummy time ready for prime time?	118
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges	118
Extracorporeal cardiopulmonary resuscitation: not why, but how	117
Trump administration decimates worker health oversight	113
Correction to Lancet Respir Med 2021; 9: 1275–87	112
Improving lifelong respiratory health after preterm birth	111
Chronic cough as a disease: implications for practice, research, and health care	111
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial	110
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study	110
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis	109
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub	108
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial	107
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis	107
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s	106
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co	106

Nintedanib for treating progressive fibrosing interstitial lung diseases	105
Venus and Mars: chest wall deformity and thoracic disease	104
Trouble with promoting lung cancer screening in never-smokers	104
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial	104
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO	103
COPD: a complex, multifactorial, but preventable disease?	101
Underappreciated causes of obstructive lung disease	97
Spirometry in female individuals – Authors' reply	95
Correction to Lancet Respir Med 2023; 11: 1064–74	95
Health effects from climate-driven events: lessons learnt	93
Prevalence of sleep-disordered breathing in an African general population: The Benin Society and Sleep (BeSAS) study	92
Unveiling a hidden phenotype of early tuberculosis	92
Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial	91
COP27 Climate Change Conference: urgent action needed for Africa and the world	91
Developments and priorities in bronchiectasis research	91
Liberal or restrictive transfusion for VV ECMO	90
Tackling tuberculosis: what lies beneath the surface?	89
Realignment of clinical research after the COVID-19 era	89
Opioid use and sleep apnoea	89
Clean air, climate targets, and respiratory health in Europe	88
Choice overload for RSV prevention—how to form your opinion	88
Unavailability of varenicline: a global tragedy for the fight against the tobacco epidemic	87
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma	87
Management after combined BPA and medical therapy in CTEPH: time for cardiopulmonary exercise testing	86
Pre-COPD: an evolving concept with practice potential	85
Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven ot	83
Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial	81
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis	81
Early-life respiratory syncytial virus disease and long-term respiratory health	81
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials	79
The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study	78
SIMPLIFYing cystic fibrosis treatment in a post-modulator era	78
Correction to Lancet Respir Med 2021; published online June 18. https://doi.org/10.1016/S2213-2600(21)00089-8	78
Society of Critical Care Medicine Critical Care Congress 2023	75
E-cigarette company tactics in sports advertising	73
The recent explosion in snortable energy powder consumption	71
Correction to Lancet Respir Med 2022; published online Feb 25. https://doi.org/10.1016/S2213-2600(22)00045-5	71
Treating acute respiratory illness: the need to be proactive	71
Time-dependent bias when analysing COVID-19-associated pulmonary aspergillosis – Authors' reply	69
Collateral caring	69
COVID-19—an infectious disease in the top five causes of death in Australia	68
Pioneering a paradigm shift in asthma management: remission as a treatment goal	67
Wildfires in southern California: concerns for lung health	67
Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement	66
Core outcome measurement instruments for use in clinical and research settings for adults with post-COVID-19 condition: an international Delphi consensus study	65
Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial	64
Breathing barriers: bridging lung health, research, and awareness	63
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial	62
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial	62
Managing tuberculosis before the onset of symptoms	61
The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial	61
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial	60
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from tw	60
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis	59
Home monitoring in interstitial lung diseases	59
Sanjay Ramakrishnan—several lucky turns to arrive at COPD	58
Cardiac and vascular serious adverse events following tixagevimab–cilgavimab	56
NUTRIREA-3: where to next?	56
Continued enteral nutrition until extubation compared with fasting before extubation in patients in the intensive care unit: an open-label, cluster-randomised, parallel-group, non-inferiority trial	55
Moving forward in IPF: lessons learned from clinical trials	55
Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia	53
The importance of post-tuberculosis morbidity in high-income countries	52
Waning immunity to SARS-CoV-2: implications for vaccine booster strategies	52
Continuing ECMO with no possible transition to recovery or transplant	52
General population-based lung function trajectories over the life course: an accelerated cohort study	51
What is adequate preoxygenation? – Authors' reply	51
Trial emulation with observational data in cystic fibrosis	51
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial	51
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	51
Tackling the global burden of lung disease through prevention and early diagnosis	50
Common and rare variants and survival in idiopathic pulmonary fibrosis	49
Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis	49
Do B cells rather than eosinophils drive chronic rhinosinusitis with nasal polyps?	49
Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multi	49
Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled c	49
Correction to Lancet Respir Med 2025; 13: 800–08	48
Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study	47
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and	47
Rise in group A streptococcal infections in England	47
Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies	46

Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicent	45
Postoperative CPAP after major abdominal surgery – Authors' reply	45
US Senate announces planned gun reforms after latest school shooting	44
Lifting the veil on humour and anaesthetics	44
The upcoming influenza season and protection from vaccines	44
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO – Authors' reply	43
Correction to Lancet Respir Med 2023; published online Feb 3. https://doi.org/10.1016/S2213-2600(22)00491-X	42
European Lung Cancer Congress 2024	42
Flavia Machado—a Latin American leader in sepsis	42
Neomi Shah—cracking the conundrum of sleep disorders	42
Guidelines might help reduce the burden of asthma in African children	42
Community-acquired pneumonia: the best candidates for clarithromycin	42
ECMO: more than just a bridge over troubled waters?	41
Reflections 5 years on from the approval of ETI therapy	41
Perioperative lung expansion and pulmonary outcomes after abdominal surgery	41
International guideline recommendations and eligibility criteria for home oxygen therapy	40
Chronic respiratory disease in Indigenous peoples: a framework to address inequity and strengthen respiratory health and health care globally	40
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomi	40
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised,	39
Oral corticosteroids for acute preschool wheeze	39
Surviving sepsis with multiple serious complications	39
Changes in rates of prescriptions for inhaled corticosteroids during the COVID-19 pandemic	39
Patient in her 70s with COPD and asthma improving significantly since using monoclonal antibody dupilumab	39
Use of lung-cancer trends for global and public health priorities	38
Stubble: the Farmer's Bane	38
Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts	37
Correction to Lancet Respir Med 2024; 12: 544–55	37
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study	36
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management	36
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study	36
Surviving COVID-19: a familiar road to recovery?	36
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study	36
Effect of non-invasive ventilation after extubation in critically ill patients with obesity in France: a multicentre, unblinded, pragmatic randomised clinical trial	36
Fighting sepsis: still a long way to go	36
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial	36
It is time to include real-world effectiveness data on medicinal product labels	35
High-dose rifampicin to treat tuberculosis infection: potential and pitfalls	35
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled,	35
US EPA strengthens PM2·5 air pollution limits	35
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study	35
Discussions on VT4COVID	34
Correction Lancet Respir Med 2022; 10: 937–48	34
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply	34
Home-based monitoring in chronic respiratory diseases: in search of Panacea	33
Correction to Lancet Respir Med 2025; 13: 318–26	33
C-reactive protein-guided treatment in pneumonia: charting a personalised approach – Authors’ reply	33
Concerns regarding a suggested long COVID paradigm	33
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?	33
Outcome predictors and patient progress following delivery in pregnant and postpartum patients with severe COVID-19 pneumonitis in intensive care units in Israel (OB-COVICU): a nationwide cohort study	33
Air pollution, climate change, and lung health in Europe	32
The passage of Ireland's Human Tissue Act: challenges, consequences, and cross-border cooperation	32
Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial	31
Preoxygenation strategies for intubation: a closer look at inclusion criteria and patient heterogeneity – Authors' reply	31
How Glasgow's 1957 tuberculosis screening programme could help countries today	31
Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome	31
Convalescent plasma in outpatients with COVID-19	31
Arrival of biosimilars in respiratory medicine: towards improved access to biologics for patients	31
Unseen collateral damage: tackling preventable morbidity and mortality in family members of ICU decedents	30
Continued resuscitation at the scene versus early transport for refractory out-of-hospital cardiac arrest	30
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-	30
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 tria	29
Remdesivir saves lives. Were 3 years needed to learn that?	29
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial	29
The carbon footprint of inhaled medications in Australia	29
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomise	28
SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys	28
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis	28
Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care	28
Tuberculosis prevalence: beyond the tip of the iceberg	28
Addressing the origins and health effects of small lungs	27
Lockdown as the mother of invention: disruptive technology in a disrupted time	27
Trouble with promoting lung cancer screening in never-smokers – Authors' reply	27
Concerning the use of aminoglycosides in ventilator-associated pneumonia – Authors' reply	27
The future of paediatric acute respiratory distress syndrome	27
Time to move away from an oxygen-centric model of pulmonary infarction? – Authors' reply	27
The Wuhan lockdown	26
Correction to Lancet Respir Med 2022; 10: 327–36	26
Confounding undermines inferences of preventive therapy effectiveness among subgroups of tuberculosis contacts	26
Living with spinal muscular atrophy while working in critical care	26
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study	26
European Respiratory Society International Congress 2024	26
Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa	26
Treatment strategy for EGFR mutated NSCLC	25
COVID-19-related ARDS: one disease, two trajectories, and several unanswered questions	25
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study	25
Effects of SARS-CoV-2 on prenatal lung growth assessed by fetal MRI	24
What is next for BCG revaccination to prevent tuberculosis?	24
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open	24
Navigating uncertainty: asthma biologics during pregnancy	24
Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise	24
Phenotypes of idiopathic pulmonary arterial hypertension	24
Idiopathic inflammatory myopathies related lung disease in adults	23
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials	23
Sedative medications: an avoidable cause of asthma and COPD exacerbations?	23
Volcanic eruption in Tonga and effects on respiratory health	23